智通财经网·2025-11-18 08:42Core Viewpoint - The company has entered into a memorandum of understanding with Watson Bio-Tech to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1][2] Group 1: Partnership Details - The memorandum outlines collaboration in establishing an RNA-centered research center in Singapore, integrating proprietary disease RNA databases with Watson's mRNA technology to advance RNA-based diagnostic products, vaccines, and therapeutics [1] - The partnership aims to accelerate clinical trials and regulatory approvals for existing and pipeline products in the ASEAN region [1] - A sales and distribution platform will be set up in Singapore to serve the ASEAN region and specific international markets for existing and pipeline products [1] - A supply chain will be established in Singapore to coordinate end production, quality, and commercial deployment of existing and pipeline products [1] Group 2: Strategic Value - The partnership is expected to generate significant strategic value, reinforcing the company's position as a pillar in the growing RNA diagnostics and therapeutics ecosystem in the region [2] - It will expand the company's product portfolio in early detection and prevention solutions, accelerating revenue growth [2] - The RNA-centered platform will facilitate collaboration with global institutions to seize and expand regional opportunities [2] - The collaboration is anticipated to promote cross-border joint investment and cooperation opportunities, enhance corporate visibility, deepen R&D capabilities, and contribute to the long-term development and revenue diversification of the group [2]